Similarly, 25% of patients (8 of 32) with HER2-positive tumours (irrespective of HR status), treated with trastuzumab and chemotherapy (n = 56), and high NOTCH1 mRNA expression experienced an RFI event, and only 4% of patients (1 of 24) with low NOTCH1 mRNA expression (adjusted hazard ratio = 6.6, 95% CI 0.82–52.61) (Fig. 2F, Supplementary Table S4A). This evidence concerns the gene ERBB2 and neoplasm.